等待開盤 09-20 09:30:00 美东时间
-0.020
-0.38%
Exscientia press release (NASDAQ:EXAI): Q2 GAAP EPS of -$0.36. Revenue of $5.6M (+47.4% Y/Y). More on Exscientia Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others Exscientia...
08-16 13:57
Exscientia Plc (EXAI) has released an update. Exscientia Plc is set to revoluti...
08-15 19:47
Barclays analyst Peter Lawson downgrades Exscientia (NASDAQ:EXAI) from Overweight to Equal-Weight and announces $5 price target.
08-14 01:34
8月8日,利用人工智能发现新药的生物科技公司Recursion Pharmaceuticals (RXRX.O)已同意收购规模较小的竞争...
08-12 10:11
Exscientia Plc (EXAI) has released an update. Exscientia plc, an England and Wa...
08-09 05:50
Exscientia Plc (EXAI – Research Report) received a Hold rating and price target...
08-09 04:25
格隆汇8月8日|Recursion和Exscientia plc今天宣布两家公司已达成最终协议,将Recursion和Exscientia合并。Recursi...
08-08 22:07
人工智能驱动的药物研发公司Recursion Pharmaceuticals(RXRX.US)已同意以6.88亿美元的价格全股票交易收购规模较小的竞争对手Exscientia(EXAI.US)
08-08 21:38
Exscientia (NASDAQ:EXAI), an AI-driven drug discovery firm, has agreed to be acquired by its larger peer, Recursion Pharmaceuticals (NASDAQ:RXRX), whose backers include chipmaker Nvidia (NASDAQ:NVDA),...
08-08 19:54